Study: NCT01411267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day IV on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day IV on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day IV on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day IV on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day IV on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day IV on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day IV on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day IV on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day IV on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2/day IV on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~* 6 mg for patients age \< 1yr~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~* 6 mg for patients age \< 1yr~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~* 6 mg for patients age \< 1yr~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~* 6 mg for patients age \< 1yr~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age